The new understanding of molecular events that drive the various forms of amyloidosis has led to the expansion of therapeutic options to prevent end-stage disease or even offer a cure, which has added ...

Interviewer: Amyloidosis is a rare and possibly debilitating disease, which affects about 4,000 people a year in the United States. If left untreated, the disease can cause severe organ damage, so ...

AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) approved ...

The first and only treatment for a rare and often fatal blood cell disorder has been approved in the United States. The new indication is newly diagnosed light-chain (AL) amyloidosis, which affects ...

Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA ...

COVID-19 and Cancer Care: Ensuring Safety While Transforming Care Delivery This was a phase III, multicenter, randomized, open-label trial. Patients were stratified according to cardiac stage.

Multiple myeloma and amyloidosis begin the same way – in plasma cells, white blood cells that help your immune system. But multiple myeloma (MM) is a rare blood cancer while amyloidosis is a buildup ...

The Amyloidosis Program at University of Utah Health and Huntsman Cancer Institute is one of the few programs in the United States specifically designed to treat amyloidosis and provide ...

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially ...